Introduction
============

Small-cell lung cancer (SCLC) accounts for ∼15%--20% of all lung cancers.[@b1-ott-9-5761] It is characterized by extremely aggressive biological nature, rapid growth, and early metastasis. Although SCLC is highly responsive to chemoradiotherapy (CRT) initially, it tends to recur and have devastating prognosis. The median survival time is only 15--20 months for limited-stage (LS) and 8--13 months for extensive-stage (ES) SCLC.[@b2-ott-9-5761]--[@b4-ott-9-5761] Because of the aggressive biological nature and high mortality of SCLC, it might be helpful to have an effective biomarker that helps monitoring disease progression, adjusting treatment plans, and preventing overtreatment.

In the 19th century, Rudolf Virchow first observed leukocytes within tumors, indicating a possible link between tumor progression and inflammation. Afterward, tumor-associated inflammation was shown to play a critical role in tumor development, including tumor initiation, progression, transformation, invasion, and metastasis.[@b5-ott-9-5761] Moreover, tumor-associated inflammation could inhibit host immune response and enhance genomic instability, which is an important cause for cancer initiation. de Visser et al[@b6-ott-9-5761] illustrated that chronic inflammation disturbed the interactions between host immune cells because of abnormal cellular profiles, soluble mediators, and signal pathways. Further, the destructive circumstances lead to genomic instability and increased risk of cancer development. The most direct evidence of the association between cancer development and chronic system inflammation comes from patients treated with chronic inflammation inhibitors, who were prone to cancer progression before treatment and could achieve chemopreventative potential afterward. It has been reported that the inflammation inhibitors such as aspirin and selective cyclooxygenase-2 inhibitors could significantly decrease cancer risk.[@b7-ott-9-5761] As a paraneoplastic surrogate index for host immune response and inflammation status, the prognostic value of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) has been demonstrated in a variety of cancers, including colorectal cancer, gastric cancer, esophageal cancer, non-small-cell lung cancer, breast cancer, ovarian cancer, and endometrial cancer,[@b8-ott-9-5761]--[@b14-ott-9-5761] but it was rarely reported in SCLC. Therefore, in this study, we verified the prognostic value of NLR and PLR in SCLC patients and provide informative knowledge to the disease prognosis.

Materials and methods
=====================

Patient characteristics
-----------------------

We retrospectively analyzed 153 patients who were diagnosed with SCLC between January 2009 and September 2013 in Shandong Cancer Hospital and Institute. The study protocols were approved by the Ethics Committee of Shandong Cancer Hospital and Institute, People's Republic of China. All participants provided written informed consent. All the included patients were pathologically diagnosed with SCLC by biopsy. The patients with LS SCLC received combined concurrent CRT or sequential CRT, and they received combination chemotherapy as first-line treatment for at least two cycles, which was based on platinum agents such as cisplatin and carboplatin. The radiation modes for all LS SCLC patients were conventional fraction radiotherapy and accelerated hyperfractionation, with the total dose of radical thoracic radiation (TRT) ranging from 45 Gy to 62 Gy. After radical TRT, patients who achieved complete response or nearly complete response received prophylactic cranial irradiation. The majority of the patients with ES SCLC received combined sequential CRT, and only a few of them received concurrent CRT. The radiation modes also included conventional fraction radiotherapy and accelerated hyperfractionation, with the total dose of palliative TRT ranging from 30 Gy to 60 Gy. Prophylactic cranial irradiation was implemented for patients who achieved high response rate. Computed tomography scan was used to evaluate treatment response based on evaluation criteria in solid tumors (RECIST) Version 1.1.[@b15-ott-9-5761]

Data collection
---------------

The clinical baseline data of patients' characteristics were obtained from the electronic medical record system of Shandong Cancer Hospital and Institute. The following parameters were recorded: demographics, smoking habits, disease stage, Karnofsky performance status, inflammation situation, granulocyte-macrophage colony-stimulating factor (GM-CSF), and radiation modes. Besides this, hemoglobin, albumin, lactate dehydrogenase, and alkaline phosphatase were evaluated at diagnosis. Absolute blood cell counts of neutrophils, lymphocytes, and platelets were collected at four time points, which were at diagnosis, after the first cycle of chemotherapy, after radiotherapy, and at disease progression. GM-CSF is often administered when absolute white blood cell count is \<3,000 cells/mL. The NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count. The PLR was defined as the absolute platelet count divided by the absolute lymphocyte count.

Statistical analysis
--------------------

The optimal cutoff values of NLR and PLR were set at where the receiver operating characteristic curve yielded the combined maximum of sensitivity plus specificity. Primary and secondary end points were overall survival (OS) and progression-free survival (PFS), respectively. OS was defined as the time from diagnosis to death, from any cause, or to the last follow-up date. PFS was defined as the time from diagnosis until evidence of disease progression, including thorax failure or distant metastasis. OS and PFS were performed using Kaplan--Meier method, and comparisons were carried out by log-rank test. Continuous variables of patients were summarized by mean values with standard deviation. The comparisons between high-and low-NLR/PLR groups were performed with Mann--Whitney *U*-test or Wilcoxon signed-rank test. Categorical variables were summarized by frequencies and analyzed with chi-square tests or two-sided Fisher's exact test. To determine the independent prognostic factors, a multivariate analysis was performed using Cox proportional hazards model, and hazard ratios were reported as relative risks with corresponding 95% confidence intervals. All tests were two sided, and *P*\<0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

A total of 153 SCLC patients were treated with CRT during the study period. In the end, we had NLR and PLR data for all the patients at diagnosis, 145 patients after first cycle of chemotherapy and after radiotherapy and 69 patients at disease progression point. The basal levels of patient characteristics are shown in [Table 1](#t1-ott-9-5761){ref-type="table"}. Patients' median age at diagnosis was 62 years (range 28--79 years). The median PFS was 11.0 months (1.2--67.7 months), and median OS was 23.3 months (6.0--70.2 months). Applying receiver operating characteristic analysis, the optimal cutoff values were 3.2 for NLR, with area under the curve (AUC) of 0.723, and 122.7 for PLR, with AUC of 0.623.

We also summarized the changes of NLR and PLR along with the progression of disease and treatment, as shown in [Table 2](#t2-ott-9-5761){ref-type="table"}. NLR decreased after one cycle of chemotherapy compared to the time of diagnosis (2.87±1.60 vs 3.26±1.36, *P*=0.016), and then it significantly increased after TRT (8.98±9.96 vs 3.26±1.36, *P*\<0.01). At disease progression point, NLR decreased again but was still higher than the level at the time of diagnosis (4.27±3.70 vs 3.26±1.36, *P*=0.499).

In contrast, PLR increased after one cycle of chemotherapy compared to the time of diagnosis (182.18± 94.30 vs 151.50±60.01, *P*\<0.01), and then it significantly increased again after TRT (308.49±252.23 vs 151.50±60.01, *P*\<0.01). At disease progression point, PLR decreased but was still higher than the level at the time of diagnosis (193.58±106.35 vs 151.50±60.01, *P*=0.026).

Factors associated with NLRand PLR
----------------------------------

The associations between clinical features of patients and NLR or PLR values are summarized in [Table 3](#t3-ott-9-5761){ref-type="table"} with NLR-or PLR-based stratifications. From the comparisons, we found more ES SCLC patients in the high-NLR group (*P*\<0.01), which also had worse Karnofsky performance status (*P*=0.043), lower serum albumin level (*P*=0.005), lower response rate for initial chemotherapy (*P*=0.027), lower prophylactic cranial irradiation rate (*P*=0.004), less radiation therapy dose (*P*=0.047), and lower second-line chemotherapy rate (*P*=0.006). For PLR-based stratification, we also found more ES SCLC patients in the high-PLR group (*P*=0.009), which had lower response rate for initial chemotherapy (*P*=0.041) and lower second-line chemotherapy rate (*P*=0.038).

From [Table 3](#t3-ott-9-5761){ref-type="table"}, we could see that both NLR and PLR had predictive abilities for initial chemotherapy response. The response rate is 94.0% for low-NLR group versus 77.1% for high-NLR group (*P*=0.027) and 93% for low-PLR group versus 78.1% for high-PLR group (*P*=0.041).

Prognostic significance of NLR and PLR at diagnosis
---------------------------------------------------

In the univariate analysis, high NLR, elevated alkaline phosphatase, high stage, and high NLR plus high PLR at diagnosis were significantly associated with both shorter OS and PFS. However, high PLR was associated only with shorter OS. Besides this, the administration of GM-CSF was not associated with better OS or PFS ([Table 4](#t4-ott-9-5761){ref-type="table"}). Therefore, all these factors were included in the subsequent multivariate analysis. The result of multivariate analysis showed that both high NLR at diagnosis and high stage were independent prognostic factors for shorter OS and PFS ([Table 5](#t5-ott-9-5761){ref-type="table"}).

The optimal cutoff values were 3.2 for NLR, with AUC of 0.723, and 122.7 for PLR, with AUC of 0.623. Based on these cutoff values, patients were stratified into two groups. Survival was analyzed using the Kaplan--Meier method with this stratification ([Figure 1](#f1-ott-9-5761){ref-type="fig"}). The results showed that low-NLR group was significantly associated with better OS (low vs high, 31.0 months vs 18.0 months, *P*\<0.01) and better PFS (low vs high, 13.0 months vs 9.3 months, *P*\<0.01). The cumulative 3-year OS rates were 37.3% in low-NLR group and 14.3% in high-NLR group. The cumulative 3-year PFS rates were 22.9% in low-NLR group and 8.6% in high-NLR group. However, low-PLR group was significantly associated only with better OS (low vs high, 31.0 months vs 20.7 months, *P*=0.036). The cumulative 3-year OS rates were 36.8% in low-PLR group and 20.8% in high-PLR group.

Since disease stage had a significantly differential distribution between NLR groups, we also analyzed the associations between NLR and survival based on disease stage at diagnosis ([Figure 2](#f2-ott-9-5761){ref-type="fig"}). For LS SCLC, low-NLR group was significantly associated with better OS (low vs high, 33.7 months vs 24.5 months, *P*=0.019), but not for PFS (low vs high, 26.2 months vs 12.0 months, *P*=0.052). Similarly, for ES stage, low-NLR group was significantly associated with better OS (low vs high, 17.3 months vs 13.3 months, *P*=0.03), but not for PFS (low vs high, 8.7 months vs 8.1 months, *P*=0.115).

Discussion
==========

In this study, NLR at diagnosis was an independent prognostic factor, and high NLR was significantly associated with shorter OS and PFS in SCLC patients who received standard therapy. As an index of circulating immune cells, NLR could reflect the balance between system inflammation and host immune response for tumor progression, which might account for its predictive value in clinical outcomes. Similar results were also observed in studies on different kinds of cancers, such as esophageal cancer, advanced gastric cancer, colorectal cancer, breast cancer, non-small-cell lung cancer, and epithelial ovarian cancer. Recently, Shao and Cai[@b16-ott-9-5761] published a study that showed that high pretreatment NLR predicts recurrence and poor prognosis for combined SCLC. In their study, the cutoff value of NLR was 4.15, which is comparable to 3.2 of our study. Though these two cutoff values were distinct, both these studies demonstrated a powerful prognostic value of pretreatment NLR in SCLC patients. In another study conducted by Xie et al,[@b17-ott-9-5761] 938 patients were enrolled including 555 ES SCLC and 383 LS SCLC patients. They found that elevated NLR was an independent prognostic factor for poor OS in ES SCLC patients, whereas elevated PLR was an independent prognostic factor for poor OS in LS SCLC patients. However, we demonstrated that elevated NLR was an independent prognostic factor for poor OS in both ES SCLC and LS SCLC patients. The small sample size of our study may account for the discrepancy between these two studies. The prognostic value of PLR is limited in our study. Though patients with low PLR at diagnosis showed obviously prolonged OS compared to high-PLR group in the univariate analysis, PLR did not show prognostic significance in the multivariate analysis. Nevertheless, the prognostic value of PLR has been demonstrated in some other studies related to hepatocellular carcinoma, soft-tissue sarcoma, and non-small-cell lung cancer.[@b18-ott-9-5761]--[@b20-ott-9-5761] Gu et al demonstrated that high PLR predicted poor OS and poor PFS in a meta-analysis that included eleven studies with 3,430 patients. However, subgroup analysis showed that the prognostic role of PLR was detected only in Caucasians but not in Asians. The ethnic heterogenicity may be the potential reason. This discrepancy might be caused by the small sample size of our study, in which the low-PLR group only included 57 patients.

Many studies have demonstrated that tumor-associated inflammation plays a critical role in tumor progression, and the functions of tumor-associated neutrophils are very important. Although these neutrophils have two opposite roles, antitumorigenic and protumorigenic,[@b21-ott-9-5761] several studies have suggested that they mostly have the protumorigenic function that contributes to tumor growth and immunosuppression, and the depletion of these neutrophils could inhibit tumor growth.[@b22-ott-9-5761]--[@b24-ott-9-5761] Furthermore, Spicer et al[@b25-ott-9-5761] found that neutrophils could facilitate cancer cell adhesion within liver sinusoids and promote metastasis via Mac-1-mediated interactions with cancer cells. The protumorigenic role of neutrophils has also been demonstrated in melanoma. Slattery and Cheng[@b26-ott-9-5761] found that neutrophils could influence melanoma cell adhesion and migration through the endothelium via Mac-1/ICAM-1 interactions. In addition, it is known that during antitumor immune response, lymphocytes could inhibit tumor proliferation and migration. Therefore, the NLR value, based on absolute neutrophil count to absolute lymphocyte count ratio, has prognostic significance in many types of tumors.[@b8-ott-9-5761]--[@b13-ott-9-5761] The mechanisms for the formation of specialized microenvironments ("niches") during metastasis, which consist of host cells and disseminated tumor cells, are still not clear. Labelle et al[@b27-ott-9-5761] found that platelet-derived signals for chemokine secretion played an important role in recruiting granulocytes to tumor cells, which then formed "early metastatic niches" that accelerated tumor progression. Although another two studies confirmed the prognostic value of PLR in hepatocellular carcinoma and soft-tissue sarcoma,[@b18-ott-9-5761],[@b19-ott-9-5761] we did not find the independent prognostic value of PLR for predicting clinical outcomes of SCLC patients in our study.

As shown in [Table 2](#t2-ott-9-5761){ref-type="table"}, NLR changed significantly along with disease and treatment progression. It decreased after one cycle of chemotherapy compared to the time of diagnosis and then significantly increased after TRT. At disease progression point, NLR decreased again but was still higher than the level of diagnosis. Since SCLC is highly responsive to initial CRT, the reduction of NLR after one cycle of chemotherapy was reasonable. Although we examined response for initial chemotherapy after two cycles of chemotherapy, it should still reflect the tumor burden after one cycle of chemotherapy to some degree. We found that low-NLR group had higher response rate (94.0%) than high-NLR group (77.1%). At disease progression point, NLR increased again, which suggested heavier tumor burden and relatively more immunosuppressive status compared to the time of diagnosis. However, the peak value of NLR occurred after TRT, which might be opposite to our understanding, as TRT is an optimal treatment method for SCLC patients. After analyzing original data, we found that lymphocytopenia after TRT was the main cause for the peak of NLR. Therefore, the prognostic value of NLR after TRT should be further studied. Composite stratifications together with other biomarkers may be a good way to go. In summary, we found that NLR was a good index reflecting tumor burden and host immune status, and it could help evaluating treatment response and monitoring disease recurrence.

Compared with high-NLR group, low-NLR group had significantly prolonged OS and PFS. However, high-NLR group had a lower ratio (40.0%) of LS SCLC patients than low-NLR group (69.9%), which is a selection bias that should not be ignored. Therefore, we analyzed the prognostic value of NLR using another stratification based on disease stage. For OS, low-NLR group was associated with prolonged OS either for LS SCLC or for ES SCLC, compared with high-NLR group. But for PFS, the difference was not significant for both LS SCLC and ES SCLC. The reason could be that the association between disease stage and NLR stratification for PFS is closer than that for OS in multivariate analysis. In spite of this, NLR is still suggested as an independent prognostic index for survival in our study.

One of the limitations of our study is its retrospective characterization, where we could not control the potential confounding factors. A further limitation is the small sample size, and hence a large sample size study is needed to verify our results. Although limitations exist, we cannot ignore the value of this study, which suggests NLR as an effective index to predict clinical outcomes of SCLC patients.

Conclusion
==========

As an inexpensive and readily available index, NLR has its advantage in reflecting associations between tumor-associated inflammation and tumor burden. Our study highlighted the prognostic value of NLR at diagnosis for the survival of SCLC patients.
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![Survival for SCLC patients according to NLR and PLR stratification.\
**Notes:** (**A**) OS according to NLR. Solid blue -- NLR \<3.2, solid green -- NLR ≥3.2. (**B**) PFS according to NLR. Solid blue -- NLR \<3.2, solid green -- NLR ≥3.2. (**C**) OS according to PLR. Solid blue -- PLR \<122.7, solid green -- PLR ≥122.7. (**D**) PFS according to PLR. Solid blue -- PLR \<122.7, solid green -- PLR ≥122.7.\
**Abbreviations:** SCLC, small-cell lung cancer; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; OS, overall survival; PFS, progression-free survival.](ott-9-5761Fig1){#f1-ott-9-5761}

![Survival in LS and ES patients according to NLR stratification.\
**Notes:** (**A**) OS in LS patients according to NLR. Solid blue -- NLR \<3.2, solid green -- NLR ≥3.2. (**B**) PFS in LS patients according to NLR. Solid blue -- NLR \<3.2, solid green -- NLR ≥3.2. (**C**) OS in ES patients according to NLR. Solid blue -- NLR \<3.2, solid green -- NLR ≥3.2. (**D**) PFS in ES patients according to NLR. Solid blue -- NLR \<3.2, solid green -- NLR ≥3.2.\
**Abbreviations:** LS, limited stage; ES, extensive stage; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PFS, progression-free survival; ES, extensive stage.](ott-9-5761Fig2){#f2-ott-9-5761}

###### 

Patient baseline characteristics

  Variables                                   Number of patients (%)
  ------------------------------------------- ------------------------
  Age (range), years (n=153)                  62 (28--79)
  Sex (n=153)                                 
   Male                                       118 (77.1)
   Female                                     35 (22.9)
  Smoking status (n=153)                      
   Never smoker                               47 (30.7)
   Current or ex-smoker                       106 (69.3)
  Stage (n=153)                               
   LS                                         86 (56.2)
   ES                                         67 (43.8)
  KPS at diagnosis (n=153)                    
   ≥80                                        139 (90.8)
   \<80                                       14 (19.2)
  Hb at diagnosis (n=153)                     
   Normal (≤ULN)                              146 (95.4)
   Low (\<LLN)                                7 (4.6)
  Alb at diagnosis (n=136)                    
   Normal (≤ULN)                              101 (74.3)
   Low (\<LLN)                                35 (25.7)
  LDH at diagnosis (n=136)                    
   Normal (\<ULN)                             74 (54.4)
   High (≥ULN)                                62 (45.6)
  ALP at diagnosis (n=136)                    
   Normal (\<ULN)                             126 (92.6)
   High (≥ULN)                                10 (7.4)
  NLR at diagnosis, mean ± sd                 3.26±1.36
  PLR at diagnosis, mean ± sd                 151.50±60.01
  Response for initial chemotherapy (n=153)   
   CR                                         9 (5.9)
   PR                                         131 (85.6)
   SD                                         5 (3.3)
   PD                                         8 (5.2)
  Prophylactic cranial irradiation (n=127)    
   Yes                                        30 (23.6)
   No                                         97 (76.4)
  Inflammation at diagnosis (n=153)           
   Yes                                        38 (24.8)
   No                                         115 (75.2)
  Stimulate neutrophil medicine (n=153)       
   Yes                                        121 (79.1)
   No                                         32 (20.9)
  RT dose, mean ± sd (n=153)                  53.01±6.47
  Radiation modes (n=153)                     
   Conventional fraction radiotherapy         130 (85.0)
   Accelerated hyperfractionation             23 (15.0)
  Second-line chemotherapy (n=125)            
   Yes                                        85 (68.0)
   No                                         40 (32.0)
  Survival time (n=153)                       
   Median PFS (range)                         11.0 (1.2--67.7)
   Median OS (range)                          23.3 (6.0--70.2)

**Abbreviations:** LS, limited stage; ES, extensive stage; KPS, Karnofsky performance status; Hb, hemoglobin; ULN, upper limit of normal; LLN, lower limit of normal; Alb, albumin; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; NLR, neutrophil-to-lymphocyte ratio; sd, standard deviation; PLR, platelet-to-lymphocyte ratio; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RT, radiation therapy; PFS, progression-free survival; OS, overall survival.

###### 

Change of NLR and PLR at different stages of treatment

  Value     Mean ± sd       *P*-value
  --------- --------------- -----------
  NLR       3.26±1.36       
   NLR~1~   2.87±1.60       0.016
   NLR~2~   8.98±9.96       \<0.01
   NLR~3~   4.27±3.70       0.499
  NLR~1~    2.87±1.60       
   NLR~2~   8.98±9.96       \<0.01
   NLR~3~   4.27±3.70       0.012
  NLR~2~    8.98±9.96       
   NLR~3~   4.27±3.70       \<0.01
  PLR       151.50±60.01    
   PLR~1~   182.18±94.30    \<0.01
   PLR~2~   308.49±252.23   \<0.01
   PLR~3~   193.58±106.35   0.026
  PLR~1~    182.18±94.30    
   PLR~2~   308.49±252.23   \<0.01
   PLR~3~   193.58±106.35   0.508
  PLR~2~    308.49±252.23   
   PLR~3~   193.58±106.35   \<0.01

**Abbreviations:** NLR, neutrophil-to-lymphocyte ratio at diagnosis; PLR, platelet-to-lymphocyte ratio at diagnosis; sd, standard deviation; NLR~1~, neutrophil-to-lymphocyte ratio after one cycle of chemotherapy; NLR~2~, neutrophil-to-lymphocyte ratio after thoracic radiotherapy; NLR~3~, neutrophil-to-lymphocyte ratio at progression; PLR~1~, platelet-to-lymphocyte ratio after one cycle of chemotherapy; PLR~2~, platelet-to-lymphocyte ratio after thoracic radiotherapy; PLR~3~, platelet-to-lymphocyte ratio at progression.

###### 

Clinical and laboratory features according to NLR and PLR at diagnosis

  Variables                                   NLR \<3.2, n=83    NLR ≥3.2, n=70     *P*-value   PLR \<122.7, n=57   PLR ≥122.7, n=96   *P*-value
  ------------------------------------------- ------------------ ------------------ ----------- ------------------- ------------------ -----------
  Age (range), years (n=153)                  61 (28--75)        62 (35--79)        0.321       61 (28--78)         62 (35--79)        0.621
  Sex (n=153)                                                                       0.121                                              0.465
   Male                                       60 (72.3)          58 (82.9)                      45 (78.9)           73 (76.0)          
   Female                                     23 (27.7)          12 (17.1)                      12 (21.1)           26 (24.0)          
  Smoking status (n=153)                                                            0.218                                              0.853
   Never smoker                               29 (34.9)          18 (25.7)                      17 (29.8)           30 (31.3)          
   Current or ex-smoker                       54 (65.1)          52 (74.3)                      40 (70.2)           66 (68.7)          
  Stage (n=153)                                                                     \<0.01                                             0.009
   LS                                         58 (69.9)          27 (38.6)                      43 (75.4)           52 (54.2)          
   ES                                         25 (30.1)          43 (61.4)                      14 (24.6)           44 (45.8)          
  KPS at diagnosis (n=153)                                                          0.043                                              0.481
   ≥80                                        79 (95.2)          60 (85.7)                      53 (93.0)           86 (89.6)          
   \<80                                       4 (4.8)            10 (14.3)                      4 (7.0)             10 (10.4)          
  Hb at diagnosis (n=153)                                                           1.000                                              0.212
   Normal (≤ULN)                              79 (95.2)          67 (95.7)                      55 (97.4)           87 (90.6)          
   Low (\<LLN)                                4 (4.8)            3 (4.3)                        2 (2.6)             9 (9.4)            
  Alb at diagnosis (n=136)                                                          0.005                                              0.132
   Normal (≤ULN)                              65 (83.3)          36 (62.1)                      42 (80.8)           58 (69.0)          
   Low (\<LLN)                                13 (16.7)          22 (37.9)                      10 (19.2)           26 (31.0)          
  LDH at diagnosis (n=136)                                                          0.373                                              0.647
   Normal (\<ULN)                             45 (57.7)          29 (50.0)                      27 (51.9)           47 (55.9)          
   High (≥ULN)                                33 (42.3)          29 (50.0)                      25 (48.1)           37 (44.1)          
  ALP at diagnosis (n=136)                                                          0.069                                              0.088
   Normal (\<ULN)                             75 (96.2)          51 (87.9)                      51 (98.1)           75 (89.3)          
   High (≥ULN)                                39 (3.8)           7 (12.1)                       1 (11.9)            9 (10.7)           
  PLR at diagnosis, mean ± sd (n=153)         127.08±41.07       180.47±66.04       \<0.01                                             
  NLR at diagnosis, mean ± sd (n=153)                                                           2.64±0.99           3.62±1.43          \<0.01
  Response for initial chemotherapy (n=153)                                         0.027                                              0.041
   CR                                         5 (6.0)            4 (5.7)                        2 (3.5)             2 (2.1)            
   PR                                         73 (88.0)          50 (71.4)                      51 (89.5)           73 (76.0)          
   SD                                         3 (3.6)            10 (14.3)                      1 (1.8)             16 (16.7)          
   PD                                         2 (2.4)            6 (8.6)                        3 (5.3)             5 (5.2)            
  Prophylactic cranial irradiation (n=127)                                          0.004                                              0.541
   Yes                                        23 (33.8)          7 (11.9)                       13 (26.5)           17 (21.8)          
   No                                         45 (66.2)          52 (88.1)                      36 (73.5)           61 (78.2)          
  Inflammation at diagnosis (n=153)                                                 0.326                                              0.476
   Yes                                        18 (21.7)          20 (28.6)                      16 (28.1)           22 (22.9)          
   No                                         65 (78.3)          50 (71.4)                      41 (71.9)           74 (77.1)          
  Stimulate neutrophil medicine (n=153)                                             0.346                                              0.705
   Yes                                        68 (81.9)          53 (75.7)                      46 (80.7)           75 (78.1)          
   No                                         15 (18.1)          17 (24.3)                      11 (19.3)           21 (21.9)          
  RT dose, mean ± sd (n=153)                  53.98±5.87         51.87±6.99         0.047       54.11±6.05          52.36±6.65         0.127
  Radiation modes (n=153)                                                           0.502                                              0.503
   CFR                                        72 (86.7)          58 (82.9)                      47 (82.5)           83 (86.5)          
   AHF                                        11 (13.3)          12 (17.1)                      10 (17.5)           13 (13.5)          
  Second-line chemotherapy (n=125)                                                  0.006                                              0.038
   Yes                                        48 (80.0)          37 (56.9)                      40 (78.4)           45 (60.8)          
   No                                         12 (20.0)          28 (43.1)                      11 (21.6)           29 (39.2)          
  Survival time (n=153)                                                                                                                
   Median PFS (range)                         13.0 (3.3--67.7)   9.3 (1.2--64.9)    0.006       11.0 (3.3--67.7)    10.7 (1.2--60.0)   0.315
   Median OS (range)                          31.0 (6.8--70.2)   18.0 (6.0--64.9)   \<0.01      31.0 (8.9--70.2)    20.7 (6.0--68.7)   0.015

**Note:** Data shown as n (%) unless indicated otherwise.

**Abbreviations:** NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LS, limited stage; ES, extensive stage; KPS, Karnofsky performance status; Hb, hemoglobin; ULN, upper limit of normal; LLN, lower limit of normal; Alb, albumin; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; sd, standard deviation; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RT, radiation therapy; CFR, conventional fraction radiotherapy; AHF, accelerated hyperfractionation; PFS, progression-free survival; OS, overall survival.

###### 

Univariate analysis for OS and PFS

  Variables                             OS       PFS              
  ------------------------------------- -------- -------- ------- --------
  Smoking status                                                  
   No                                                             
   Yes                                  4.707    0.03     5.43    0.02
  Stage                                                           
   LS                                                             
   ES                                   24.34    \<0.01   26.11   \<0.01
  Stimulate neutrophil medicine                                   
   Yes                                                            
   No                                   0.141    0.707    0.541   0.462
  NLR at diagnosis                                                
   Low                                                            
   High                                 18.51    \<0.01   13.83   \<0.01
  PLR at diagnosis                                                
   Low                                                            
   High                                 4.38     0.036    2.05    0.152
  NLR combined with PLR at diagnosis                              
   Both low                                                       
   One high                             0.236    0.627    0.16    0.900
   Both high                            16.635   \<0.01   9.99    0.002
  ALP at diagnosis                                                
   Low                                                            
   High                                 8.32     0.004    4.13    0.042
  NLR after one cycle of chemotherapy                             
   Low                                           0.536    0.08    0.779
   High                                 0.38                      
  NLR after TRT                                                   
   Low                                                            
   High                                 1.11     0.293    0.88    0.348
  NLR at disease progression                                      
   Low                                                            
   High                                 0.45     0.504    0.04    0.846
  PLR after one cycle of chemotherapy                             
   Low                                                            
   High                                 0.86     0.354    0.75    0.386
  PLR after TRT                                                   
   Low                                                            
   High                                 0.01     0.924    0.47    0.49
  PLR at disease progression                                      
   Low                                                            
   High                                 0.32     0.570    1.46    0.226

**Abbreviations:** OS, overall survival; PFS, progression-free survival; LS, limited stage; ES, extensive stage; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; ALP, alkaline phosphatase; TRT, thoracic radiotherapy.

###### 

Multivariate analysis for OS and PFS

  Parameter          OS          PFS                                               
  ------------------ ----------- -------------- ------- ----------- -------------- -------
  NLR at diagnosis                                                                 
   Low               Reference                          Reference                  
   High              1.724       1.116--2.663   0.014   1.589       1.049--2.406   0.029
  Stage                                                                            
   LS                Reference                          Reference                  
   ES                1.926       1.248--2.973   0.003   2.168       1.398--3.360   0.001

**Abbreviations:** OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio; LS, limited stage; ES, extensive stage.

[^1]: These authors contributed equally to this work
